These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23735449)

  • 1. Acute exacerbation among chronic hepatitis C patients: tip of the iceberg that deserves more attention.
    Wong RJ; Cheung RC
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1181-2. PubMed ID: 23735449
    [No Abstract]   [Full Text] [Related]  

  • 2. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?
    Mondelli MU
    Hepatology; 2014 Oct; 60(4):1126-9. PubMed ID: 24753082
    [No Abstract]   [Full Text] [Related]  

  • 3. A view to natural killer cells in hepatitis C.
    Shoukry NH; Pelletier S; Chang KM
    Gastroenterology; 2011 Oct; 141(4):1144-8. PubMed ID: 21875586
    [No Abstract]   [Full Text] [Related]  

  • 4. Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
    Smith JA; Kalimullah FA; Erickson CP; Peng LS
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The end of the beginning for hepatitis C treatment.
    Dieterich D
    Hepatology; 2012 Mar; 55(3):664-5. PubMed ID: 22174100
    [No Abstract]   [Full Text] [Related]  

  • 6. PegIFN/ribavirin during acute HCV coinfection.
    Bernard EJ
    IAPAC Mon; 2004 Jul; 10(7):260-1. PubMed ID: 15624247
    [No Abstract]   [Full Text] [Related]  

  • 7. Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
    Kalal C; Shukla A; Mohanka R; Vora M; Patel P; Shah S
    Hepatology; 2018 May; 67(5):2049-2050. PubMed ID: 29152769
    [No Abstract]   [Full Text] [Related]  

  • 8. Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?
    Hoefs JC; Morgan TR
    Hepatology; 2007 Dec; 46(6):1671-4. PubMed ID: 18046713
    [No Abstract]   [Full Text] [Related]  

  • 9. Pegylated interferon and ribavirin in real life: efficacy versus effectiveness.
    de Mattos AZ; de Almeida PR; Tovo CV; de Mattos AA
    Hepatology; 2010 Nov; 52(5):1867. PubMed ID: 20726033
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
    Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
    Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment strategies of acute and chronic hepatitis C].
    Gładysz A; Inglot M
    Przegl Epidemiol; 2002; 56 Suppl 5():10-5. PubMed ID: 15553066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

  • 13. Older age per se has negative effect on hepatitis C patients treated with peginterferon and ribavirin.
    Chen TM; Tung JN
    Am J Gastroenterol; 2009 Aug; 104(8):2117-9. PubMed ID: 19661945
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-acting interferon: studies on pegylated interferon].
    Ma H; Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):78-9. PubMed ID: 11856520
    [No Abstract]   [Full Text] [Related]  

  • 16. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of response of U.S. veterans to treatment for the hepatitis C virus.
    Riley TR
    Hepatology; 2008 Jan; 47(1):356; author reply 356-7. PubMed ID: 18161713
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis C treatment, HAART and side effects.
    TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C: Enhancing treatment for hepatitis C among drug users.
    Grebely J; Dore GJ
    Nat Rev Gastroenterol Hepatol; 2011 Jan; 8(1):11-3. PubMed ID: 21119610
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.